ClinicalTrials.gg
Status unknownNCT02136030Updated May 12, 2014

Liposomal Amphotericin B for the Treatment of Cryptococcal Meningitis

An interventional study of Liposomal amphotericin B and Amphotericin B-deoxycholate in Cryptococcal Meningitis, sponsored by TTY Biopharm. Status unknown at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-12.

Sponsored by TTY Biopharm · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2010), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate the safety and efficacy of liposomal amphotericin B and amphotericin B deoxycholate with or without flucytosine followed by fluconazole for the treatment of cryptococcal meningitis.

Read the detailed description

Subjects who meet all eligible requirements will be randomized into study group (Lipo-AB)or control group(Amphotericin B deoxycholate) in 2:1 ratio. Subjects will be treated with induction therapy in study group or in control group with flucytosine for at least 14 days, and followed by consolidation therapy for another 56 days after CSF sterilization.

02

Conditions studied

  • Cryptococcal Meningitis

Keywords

  • Cryptococcal meningitis
03

In context

Meningitis, Cryptococcal

54 studies on the registry are indexed under Meningitis, Cryptococcal; 6 are open to participants now.

This study's planned enrollment of 84 is below the median of 143 across 35 interventional studies indexed under Meningitis, Cryptococcal.

Browse Meningitis, Cryptococcal studies →

Lead sponsor

TTY Biopharm is the lead sponsor of 14 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults with age of at least 18 years.
  2. Within 7 days prior to, or at the time of screening visit, patient with cryptococcus meningitis, diagnosed by :

    1. CSF India ink staining positive OR
    2. CSF cryptococcal antigen test positive OR
    3. CSF culture positive
  3. Patient or his/her legally acceptable representative has signed the written form.

Exclusion criteria

Exclusion Criteria:

  1. Patients have laboratory abnormalities within 3 days prior to screening visit :

    1. > 5x UNL,
    2. AST > 5x UNL,
    3. Creatinine > 2mg/dl
  2. Patient is pregnant or lactating.
  3. Patient participate other drug trial within 1 month before entering this study.
  4. Patient has some indications that another systemic antifungal drug would be needed in addition to assigned drugs in study.
  5. Patient had of amphotericin B or azole.
  6. Patient is not available for lumbar puncture.
  7. Patient with less than 5 days.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Lipo-AB

    Drug: Liposomal amphotericin B

  • Active comparator
    Amphotericin B

    Drug: Amphotericin B-deoxycholate

Interventions

  • 4mg/kg/day, IV infusion

    Also known as: Lipo-AB

  • DrugAmphotericin B-deoxycholate

    1mg/kg/day, IV infusion

    Also known as: Amphotericin B

06

What researchers measure

Primary outcomes

  1. suscceful response rate

    Successful response was defined as both satisfactory clinical and microbiological response at the completion of 14 days treatment period.

    Time frame: Day 14

07

Study locations

1 of 1 sites recruiting
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
    Recruiting
08

References and documents

Publications

  • Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010 Feb 1;50(3):291-322. doi: 10.1086/649858. PubMed 20047480 ↗
  • Adler-Moore JP, Gangneux JP, Pappas PG. Comparison between liposomal formulations of amphotericin B. Med Mycol. 2016 Mar;54(3):223-31. doi: 10.1093/mmy/myv111. Epub 2016 Jan 14. PubMed 26768369 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 12, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02136030
Lead sponsor
TTY Biopharm
Responsible party
Sponsor
First posted
May 12, 2014
Start date
Feb 2011
Primary completion
Dec 2015 (estimated)
Completion
Dec 2016 (estimated)
Last update
May 12, 2014

Study contacts

Yee-chun Chen, MD
Contact
yeechunchen@gmail.com
886-2-2312-3456 ext. 65054
Po-Liang Lu, MD
Contact
d830166@cc.kmc.edu.tw
886-7-3121101 ext. 5675
Yee-chun Chen, MD
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal amphotericin B

Start the discussion